NCT05323227 (CHART-ACCORD) is a clinical trial of Coronary CTA in Coronary Artery Disease, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT05323227?

NCT05323227 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT05323227?

Interventions in NCT05323227: Coronary CTA.

What condition does NCT05323227 study?

NCT05323227 studies Coronary Artery Disease.

Is NCT05323227 still recruiting?

NCT05323227 is currently status unknown. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT05323227: CHART-ACCORD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lp(a) With CCTA Assessed Parameters and Clinical Outcomes

Status unknown Last updated 12 April 2022

What this trial tests

trial testing Coronary CTA in Coronary Artery Disease in 378 participants. Status unknown.

Timeline

20 March 2016

Primary endpoint
30 April 2022

30 May 2022

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	378
Start date	20 March 2016
Primary completion	30 April 2022
Estimated completion	30 May 2022
Sites	1 location across China

Drugs / interventions tested

Coronary CTA

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Shanghai Zhongshan Hospital

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lipoprotein(a) \[Lp(a)\] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed tomography angiography (CCTA) as well as their prognostic value.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography-Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes.
Dai N, Chen Z, Zhou F, Zhou Y, et al · · 2022 · cited 27× · PMID 36503252 · DOI 10.1161/circimaging.122.014611

Verify or expand the search:

Other trials of Coronary CTA

Trials testing the same drug.

NCT07460583 — ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes · NA · not yet recruiting

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05323227 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05323227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing